H Lundbeck A/S

Research H Lundbeck A/S (HLUN-B) on Bullrun: valuation model: 60.9% undervalued, market cap DKK 42.40B, P/E 11.4, dividend yield 2.7%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerHLUN-B
• ExchangeCO
• CountryDenmark
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencyDKK
• Valuation signal60.9% undervalued
• Market capDKK 42.40B
• P/E11.4
• Dividend yield2.7%
• Financial periodFY2025
• RevenueDKK 24.63B
• Revenue growth11.9%
• Net incomeDKK 3.19B
• Free cash flowDKK 4.93B
• Gross margin82.7%

Valuation Snapshot

Bullrun's latest valuation model marks H Lundbeck A/S as 60.9% undervalued; latest market cap is DKK 42.40B; P/E is 11.4; dividend yield is 2.7%.

About H Lundbeck A/S

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression.

Frequently asked questions

Is H Lundbeck A/S overvalued or undervalued?

Bullrun's valuation model currently marks H Lundbeck A/S as 60.9% undervalued.

What is H Lundbeck A/S's market cap?

H Lundbeck A/S's market capitalization is DKK 42.40B.

What is H Lundbeck A/S's P/E ratio?

H Lundbeck A/S's price-to-earnings (P/E) ratio is 11.4.

Does H Lundbeck A/S pay a dividend?

H Lundbeck A/S has a dividend yield of 2.7%.

What does H Lundbeck A/S do?

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.